NordiClomid 25mg/tab 50 Tabletten by Nordi Pharma

Usage

1. Before beginning NordiClomid, obtain baseline bloodwork (serum LH, FSH, total testosterone) to establish your pre-PCT suppression level — this gives the duration calculation a measured starting point.
2. Wait until circulating androgen levels from your cycle have cleared sufficiently (timing varies by compound half-life) before taking the first tablet.
3. Begin the induction phase at 50 mg/day (two 25 mg tablets) for weeks one and two, taken orally with water, preferably at the same time each day to maintain consistent plasma levels.
4. Reduce to 25 mg/day (one tablet) for weeks three and four — the taper phase; note the number of tablets remaining as an easy cross-check that the course is on schedule.
5. Obtain a second bloodwork panel at day 28: if LH, FSH, and total testosterone have normalised, close the course; if markers remain sub-optimal, continue at 12.5–25 mg/day (half to one tablet) for up to two additional weeks.
6. After completing the course, schedule a final bloodwork assessment four weeks post-PCT to confirm sustained hormonal recovery independent of SERM support.

Warnings

Frequently asked questions

How many weeks should a full PCT course with Clomiphene Citrate last?

Most evidence-informed protocols set four weeks as the standard minimum, with extension to five or six weeks reserved for cases where bloodwork at day 28 shows LH, FSH, or total testosterone still below the normal reference range. Duration is not fixed by convention — it is closed when hormonal markers confirm successful recovery, making end-of-course bloodwork an essential step rather than an optional one.

What happens if you stop PCT too early before full hormonal recovery?

Ending Clomiphene Citrate therapy before gonadotropin levels and testosterone have fully normalised risks a secondary suppression episode: without continued SERM stimulation, a partially recovered HPG axis can stall or regress, prolonging the overall recovery window. Bloodwork — specifically serum LH, FSH, and total testosterone — is the only reliable method for confirming that early termination is safe rather than premature.

Can running PCT with Clomid for longer than six weeks cause harm?

Extended Clomiphene Citrate use beyond six weeks is associated with a higher incidence of visual disturbances and, paradoxically, with blunted endogenous testosterone output if continued past the point of natural recovery. The goal of PCT is to restore axis function, not to replace it indefinitely; once bloodwork confirms normalisation, continuing SERM therapy adds risk without benefit and may interfere with the sustained independent function that the course was designed to re-establish.

Why is NordiClomid's 25 mg tablet strength useful for adjusting PCT length?

The 25 mg per tablet strength is the lowest available in this product category, which gives practitioners genuine dose flexibility across the full duration of a course. Weeks one–two typically run at 50 mg/day (two tablets), while weeks three–four drop to 25 mg/day (one tablet); if extension is required, the tablet can be split to deliver 12.5 mg maintenance doses — an approach supported by HPLC content-uniformity data confirming API homogeneity throughout the compressed tablet matrix.

Does the 50-tablet pack of NordiClomid cover a standard four-week PCT in full?

Yes — a tapered four-week course at 50 mg/day for two weeks followed by 25 mg/day for two weeks consumes exactly 50 tablets: 14 days × 2 tablets plus 14 days × 1 tablet. The pack maps precisely onto this protocol with zero remainder, making dosing tracking straightforward and the completion point unambiguous. For extended courses, tablet splitting allows partial coverage into a fifth or sixth week without an additional purchase. (2) angle_used

Manufacturer

Nordi Pharma's manufacturing controls for NordiClomid are built around a single principle: the reliability of every PCT week depends entirely on the analytical certainty of every tablet. To that end, the finished-tablet release process for NordiClomid centres on content-uniformity verification — each production batch undergoes HPLC quantification against a certified Clomiphene Citrate reference standard, with results documented in a batch-specific certificate of analysis that remains traceable by lot number throughout the distribution chain. Separately, LAL endotoxin methodology — a technique more commonly associated with parenteral product release than with oral solid-dosage forms — is applied at the finished-tablet stage to confirm the absence of pyrogenic material. This dual-checkpoint release architecture means that the analytical record for a given pack of NordiClomid is not inferred from category-level averages but generated from the precise production run that produced those tablets: a distinction that matters when practitioners are building duration decisions around dose-per-tablet accuracy across a multi-week course.